PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Malottki K, Barton P, Tsourapas A, et al. Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Journals Library; 2011 Mar. (Health Technology Assessment, No. 15.14.)

List of abbreviations

ABT

abatacept

ACR

American College of Rheumatology

ADA

adalimumab

AE

adverse event

anti-CCP

anti-cyclic citrullinated peptide

ARRIVE

abatacept researched in rheumatoid arthritis patients with an inadequate anti-TNF response to validate effectiveness

ASSURE

abatacept study of safety in use with other rheumatoid arthritis therapies

ATTAIN

abatacept trial in treatment of anti-TNF inadequate responders

AZA

azathioprine

BRAM

Birmingham Rheumatoid Arthritis Model

BSRBR

British Society for Rheumatology Biologics Registry

CEAC

cost-effectiveness acceptability cure

CI

confidence interval

CRP

C-reactive protein

CyA

ciclosporin A

DANBIO

Danish Registry for Biologic Therapies in Rheumatology

DAS

Disease Activity Score

DAS28

Disease Activity Score 28

DMARD

disease-modifying antirheumatic drug

EQ-5D

European Quality of Life-5 Dimensions

ERG

Evidence Review Group

ESR

erythrocyte sedimentation rate

ETN

etanercept

EULAR

European League Against Rheumatism

Fc

fragment crystallisable

GO-AFTER

GOlimulab After Former anti-tumour necrosis factor Therapy Evaluated in Rheumatoid arthritis

GP

general practitioner

GST

injectable gold

HAQ

Health Assessment Questionnaire

HAQ DI

Health Assessment Questionnaire Disability Index

HCQ

hydroxychloroquine

HR

hazard ratio

HRQoL

health-related quality of life

HUI3

Health Utilities Index Mark 3

IC

indirect comparison

ICER

incremental cost-effectiveness ratio

IFX

infliximab

IgG1

immunoglobulin G1

IR

inadequate response

ITT

intention to treat

i.v.

intravenous

K–M

Kaplan–Meier (curve)

LEF

leflunomide

LTE

long-term extension

MCID

minimal clinically important difference

MS

manufacturer's submission

MTC

mixed-treatment comparison

MTX

methotrexate

NAO

National Audit Office

NICE

National Institute for Health and Clinical Excellence

NOAR

Norfolk Arthritis Register

NSAID

non-steroidal anti-inflammatory drug

OPPOSITE

open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept

Pall

palliation

PCT

primary care trust

PSA

probabilistic sensitivity analysis

QALY

quality-adjusted life-year

QoL

quality of life

RA

rheumatoid arthritis

RCT

randomised controlled trial

RD

risk difference

ReAct

Research in Active Rheumatoid Arthritis

REFLEX

randomised evaluation of long-term efficacy of rituximab in rheumatoid arthritis

RF

rheumatoid factor

RR

relative risk

RTX

rituximab

SD

standard deviation

SF-36

Short Form questionnaire-36 items

SJC

swollen joint count

SSTAG

Southern Swedish Arthritis Treatment Group Registry

STA

single technology appraisal

SUNRISE

study for understanding rituximab safety and efficacy

TB

tuberculosis

TEMPO

Trial of Etanercept and Methotrexate with radiographic Patient Outcomes

TJC

tender joint count

TNF

tumour necrosis factor

TNFα

tumour necrosis factor alpha

TOC

tocilizumab

WTP

willingness to pay

All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices, in which case the abbreviation is defined in the figure legend or in the notes at the end of the table.

© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Cover of Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation
Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.14.
Malottki K, Barton P, Tsourapas A, et al.
Southampton (UK): NIHR Journals Library; 2011 Mar.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...